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Fig. 1 demonstrates dose prescription protocols (DPP) of the 




Results: As previously reported (ESTRO 2015) we 
unexpectedly observed late grade (G)3 and 4 mucosal ulcers 
in 1/7 and 3/7 DPBN-patients in DPP1, respectively, that 
healed spontaneously (n = 1), after surgical intervention (n = 
2) and is still persisting (n = 1) at 42 months. In order to 
avoid G4 mucosal late toxicity (LT) the DPBN-DPP has been 
adapted in 2 steps (Fig. 1): DPP1 used a median dose 
prescription that can result in increased doses in a GTV with 
> 50% voxels of low-uptake. This median dose prescription 
was abandoned in DPP2. In DPP3 the very-high dose region is 
limited to an absolute volume of 1.75 cc. In DPP2, 1/2 had 
G3 mucosal LT that healed spontaneously. In DPP3, 2/11 and 
1/11 had G3 and G4 mucosal LT, respectively. In S-IMRT, 
there was no G3-4 mucosal LT (n = 20). Late G3 dysphagia 
was seen in 2/18 and 3/20 DPBN and S-IMRT patients at 
month 3, respectively. After 6 months, 6/15 and 2/13 
patients had G≥2 d ysphagia (p = 0.22) and PEG-tube was 
needed in 5/15 and 3/13 patients in DPBN and S-IMRT, 
respectively. G2 xerostomia was present in 6/13 and 7/13 
patients in DPBN and S-IMRT, respectively.  
Median follow-up is 12 (3-45) months. Nine patients 
deceased: 5 DPBN-patients (metastases in 3, complications 
after neck dissection for regional recurrence in 1 and 
unknown cause in 1) and 4 S-IMRT patients (2 metastases, 1 
aspiration pneumonia and 1 cardial event). Local failure was 
seen in 1/21 (5%) and 4/24 (17%) in DPBN and S-IMRT, 
respectively. Regional failure was seen in 2/21 (10%) and 
2/24 (8%) in DPBN and S-IMRT, respectively. Metastases were 
seen in 4/21 (19%) and 5/24 (21%) in DPBN and S-IMRT, 
respectively. At 1 year actuarial LC was 92% and 76% (p = 
0.22), RC 86% and 87% (p = 0.9), DC 76% and 86% (p = 0.9) and 
OS 68% and 90% (p = 0.6) in DPBN and S-IMRT, respectively. 
 
Conclusion: At short term, we did not observe significant 
differences yet in LC, RC, DC or OS in the first 45 patients. 
Due to mucosal LT, the DPBN-DPP has been adapted. Since 
then, G4 mucosal LT was observed in 1/12 patients. Strict 
follow-up of LT is being performed. 
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Purpose or Objective: Although several treatments have 
been evaluated in randomized clinical trials (RCTs) for Graves 
Ophthalmopathy (GO), many of these treatments have not 
been directly compared against each other and thus the 
relative efficacy among them is unclear. We conducted a 
network meta-analysis (NMA) to compare all regimens 
simultaneously. 
 
Material and Methods: A systematic review was performed 
through MEDLINE, Cochrane Central Register of Controlled 
Trials and meeting abstracts to identify RCTs involving 
treatments for GO. Treatments included: Radiation 10 Gy in 
10 fractions (RT10) or 20 Gy in 10 fraction (RT20), with oral 
glucocorticoid (RT20POGC), with intravenous glucocorticoid 
(RT20IVGC), with retrobulbar glucocorticoid injections 
(RT20RBGC); oral glucocorticoid (POGC); intravenous 
glucocorticoid (IVGC); surgical decompression (Decomp); 
somatostatin analogs i.e., Octreotide or Lanreotide (SSanlg); 
Cyclosporin alone (Cysprn), with oral glucocorticoid 
(CysprnPOGC); Ciamexone (Ciamex); rituximab (Ritux); 
peribulbar orbital glucocorticoid injection (BGCI) or no 
treatment/placebo/sham radiation (NoTx). Success of 
treatment was determined from overall clinical response, 
which was provided by most studies. If this was absent, then 
it was estimated from proportion of patient not needing 
further treatment, improvement in clinical activity score 
(CAS), ophthalmopathy index (OI) or proptosis was used in 
that order. Odds Ratio (OR) was calculated either directly or 
via standardized mean difference (SMD) in measures. A 
frequentist NMA was used to compare treatments. Fixed or 
random effect model was used based on any significant 
variation among ORs. 
 
Results: 27 studies involving 1216 patients were identified, 
with 15 distinct treatments including NoTx. Fixed effect 
model was used, as there was no significant variation among 
ORs. RT20IVGC was significantly better that BGCI (OR 31.4 
[5.1, 195.7]), Ciamex (OR 6.8 [1.4, 33.1]), Cysprn (OR 64.9 
[10.6, 398.5]), Decomp (OR 25.8 [1.7, 392.8]), IVGC (OR 4.1 
[1.5, 11.6]), NoTx (OR 18.9 [5.69, 62.6]), POGC (OR 11.8 
[4.0, 34.6]), RT10 (OR 10.1 [1.9, 52.2]), RT20 (OR 8.4 [2.7, 
25.9]), RT20POGC (OR 4.2 [1.3, 12.9]), RT20RBGC (OR 3.5 
[1.2, 10.2]) and SSanlg (OR 11.1 [3.0, 40.4]), but did not 
reach significance compared to CysprnPOGC (OR 3.7 [0.8, 
17.8]) or Ritux (OR 5.0 [0.9, 28.9]). IVGC was found to be 
significantly better than BGCI (OR 7.6), Cysprn (OR 15.7), 
NoTx (OR 4.6) and POGC (OR 2.9). Also, CysprnPOGC was 
significantly better than BGCI (OR 8.6), Cysprn (OR 17.7), 
NoTx (OR 5.1) and POGC (OR 3.2). RT20, RT20POGC and 
RT20RBGC were all significantly better than Cysprn (ORs 7.7, 
15.6 & 18.6 respectively). RT20 and RT20RBGC were better 
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than NoTx (ORs 2.3 & 5.4 respectively). Also, SSanlg was 
better than NoTx (OR 1.7). 
 
Conclusion: RT20IVGC is the best treatment followed by IVGC 
and CysprnPOGC per this NMA. Also, RT20RBGCI and SSanlg 
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Purpose or Objective: Recurrent head and neck cancer 
(HNC) after radiotherapy or surgery has many problems about 
salvage treatment options such as surgery, chemotherapy and 
radiation therapy. Stereotactic radiotherapy is one of the 
treatment options for inoperable patients. However, in many 
cases, salvage radiation (SRT) is considered as a re-
irradiation, and the treatment results of salvage radiation 
with a definitive dose for recurrent HNC are still insufficient. 
This analysis was done to reveal the treatment results and 
prognostic factors in SRT for both of locoregional and distant 
recurrences, with definitive treatment dose. 
 
Material and Methods: One hundred and three patients with 
43 local, 23 regional and 36 distant recurrences were treated 
with stereotactic radiotherapy for definitive treatment 
purpose. Treatment period was between May 1998 and July 
2014. Eighteen to 70 Gy were delivered in 3 to 20 fractions. 
Treatments were delivered with CyberKnife or Novalis 
treatment system. There were 59 patients with squamous 
cell carcinoma, 8 with adenoid cystic carcinoma, 7 with 
papillary adenocarcinoma and 26 patients with other 
histlogical type. 
 
Results: Median follow up period of survivors was 17 months 
(range 0-103), and the median survival time of all patients 
was 23 months. At 3 years, actuarial overall survival rate (OS) 
was 37%, 33% and 23%, and median survival time was 30, 26 
and 20 months for local, regional and distant recurrence, 
respectively (p =0.638). OS was significantly better in the 
patients with oligo-recurrence (p<0.001) or to whom SRT 
were done for a lesion previously untreated by surgery 
(p=0.001). Cox regression analysis indicated that factors of 
oligo-recurrence and histology except for squamous 
carcinoma had significant influence on OS. The favorable 
group having both of the two factors (n=23) showed excellent 
5 year survival as 73 % compared with 15% of unfavorable 
group. 
 
Conclusion: This study showed that SRT with definitive dose 
achieved equivalent survival regardless of recurrent site and 
revealed two prognostic factors of oligo-recurrence and non-
squamous carcinoma in the SRT for recurrent HNC. 
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Purpose or Objective: Single session radiosurgery (SRS) and 
staged radiosurgery (sSRS) have been performed in primary 
and adjuvant settings for intracranial meningioma. Although, 
different aspects of SRS and sSRS are still controversial above 
all regarding timing, prescription doses and fractionation of 
delivery. So far there are no definitive data about treatment-
related symptom control and toxicity and categorization. The 
aim of this systematic review is to summarize the data on the 
long-term efficacy and safety of SRS and sSRS for meningioma 
patients. 
 
Material and Methods: Medline and Embase databases were 
searched for relevant studies published until April 2015. 
Experimental and observational studies focused on SRS and 
sSRS for intracranial WHO grade I and II meningioma were 
included. Studies enrolling a number of patients inferior to 
five for each arm (for comparative studies) or overall (for 
non-comparative studies) were excluded. Studies including 
patients with malignant meningioma (WHO grade III), radio-
induced meningioma or patients who had previously 
undergone brain radiation therapy were excluded from our 
review. Studies including both benign and malignant 
meningiomas were considered eligible, provided that results 
were reported separately, according to histo-pathological 
subtype. The primary outcomes were disease control and 
progression-free-survival. The secondary outcomes were 
symptom control and radiation-induced toxicity. 
 
Results: Thirty-four studies fulfilled eligibility criteria. Only 
two studies were about sSRS. The estimate of disease control 
rate ranged from 87.0% to 100.0% at 5 years and from 67.0% 
to 100.0% at 10 years. The PFS rate ranged from 78.0% to 
98.9% and from 53.1% to 97.2% at 5 and 10 years, 
respectively. No meta-analysis could be performed.We meta-
analyzed symptom control and toxicity data. The overall 
frequency of symptom control was 92.3% (95% CI:88.4-95.6%), 
the overall toxicity was 8.1% (95% CI:5.2-11.5%). The overall 
relative frequency of patients with toxicity of 8.1% (95% CI: 
